Lansoprazole

Drug #1171

Lansoprazole is an acid proton pump inhibitor. Lansoprazole is a benzimidazole sulfoxide derivarive and produces long lasting inhibition of gastric acid secretion. Lansoprazole is a chiral cmpound with one chiral center, synthsized as a racemic mixture and both enantiomers are active. Chemically Lansoprazole is identified as 2-[[[3-methyl-4-(2, 2, 2-trifluoroethoxy)-2-pyridinyl] methyl] sulfinyl ]-1H-benzimidazole. Lansoprazole is effective in the treatment of duodenal or gastric ulcer, gastroesophageal reflux disease and in the treatment of zollinger-ellison syndrome. Lansoprazole is administered orally.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin and belongs to Sulphinyl Benzimidazole.

It belongs to H/K Atpase proton pump inhibitor pharmacological group on the basis of mechanism of action. It is also classified under Antacids .

Molecular Weight: 369 · pK_a: 8.85 · Solubility in Water: 1 in 33000 · Solubility in Alcohol: 1 in 53 · Non-proprietary name: Lansoprazole.

Pharmacokinetics

Absorption: Lansoprazole has an oral bioavailability is 40% (±40%).

Distribution: Lansoprazole has a volume of distribution is 24 ± 8 litre. plasma protein binding is 97-99%.

Elimination: it is metabolised via Hepatic(extensively), plasma half-life is 1-2 hr, renal excretion is 30%.

Indications

Lansoprazole is primarily indicated in conditions like Acid-related dyspepsia, Benign gastric ulcer, Duodenal ulcer, Duodenal ulcer associated with h. Pylori, Esophagitis, Gastric ulcer, Gastro-oesophageal reflux disease, Heart burn, Helico-bacter pylori positive duodenal ulcer, NSAID-associated gastric and duodenal ulcers, NSAID-associated gastric and duodenal ulcers (prophylaxis), NSAID-associated gastric or duodenal ulcers, Peptic ulcer, Resistant ulcers, Zollinger-ellison syndrome.

Lansoprazole is also indicated for secondary conditions like GI bleeding.

Contraindications

Lansoprazole is contraindicated in conditions like Liver diseases.

Dosage

Lansoprazole's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
22.5 mg	22.5 mg	Every 24h	PO	Frequency may increased to twice.15 mg/day is given on an empty stomach.
Paediatric Dosage (20kg)
15 mg	15 mg	Every 24h		30 mg or less.
30 mg	30 mg	Every 24h		More than 30 kg
Neonatal Dosage (3kg)
0 – 0	—	—		Not recommended in this age group

Drug Interactions

Unknown5 interactions

3 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Lansoprazole in overdosage may give rise to further complications which include Atrophic gastritis, Epidermal necrolysis .

Lansoprazole is known to cause more or less tolerable side effects which are usually transient. These include Constipation , Diarrhea, Headache, Nausea, Pruritus , Rashes .

Warnings / Precautions

Lansoprazole should be used with caution in patients with any pre-existing liver disease or in case of any allergy. It should be used only if clearly needed during pregnancy or lactation. Since gastric acid secretion and other phsiological functions are decreased in elderly patients lansoprazole should be administered with caution.

Interference in Pathology

Lansoprazole may interfere in the diagnosis of Elevations of SGPT and SGOT , Abnormal LFTs , Increased Alkaline Phosphatase Levels, Elevation in ALT or AST, Increased in serum creatinin.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Caps

Caps SR

Inj

Inj-IV

Pellets

Tabs

Storage Conditions

Lansoprazole should be stored Caps.

Drug Classification

1.17.1.2 — Anti-peptic ulcerants